SABS
Closed
Sab Biotherapeutics Inc
1.76
+0.01 (+0.57%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.755
Day's Range: 1.699 - 1.776
Send
sign up or login to leave a comment!
When Written:
0.411
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company that develops and produces human polyclonal antibodies for the treatment of infectious diseases and cancer. The company's technology platform involves the use of genetically engineered cattle that produce fully human antibodies in response to an antigen. SAB's lead product candidate is SAB-185, a treatment for COVID-19 that is currently in clinical trials. The company was founded in 2014 and is headquartered in Sioux Falls, South Dakota. SAB Biotherapeutics has raised over $180 million in funding to date from investors such as Peter Thiel's Founders Fund, Bill and Melinda Gates Foundation, and others.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








